

## Monument Health Clinical Research Trials

GOLDILOX-TIMI 69

Last updated on: 8/11/2

| Heart Failure Trials | Trial Title  | ClinicalTrials.gov Link   |
|----------------------|--|---|
| HEART-FID            | Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency                             | https://clinicaltrials.gov/ctz/show/record/NCTo3037931?term=1VIT15043&rank=1  |
| HEAR I-FID           | Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Valsartan in HFpEF Patients With                   | TEEDS//CHITICALE IAIS: 201/CE2/SHOW/FECOTO/INCTO3/04/94 FEETIT = 141 FISO4 3 XI ATTX = 1  |
| PARAGLIDE HF         | Acute Decompensated Heart Failure (ADHF) Who Have Been Stabilized During Hospitalization                                   | https://clinicaltrials.gov/ct2/show/NCT03988634?term=paraglide&rank=1   |
|                      | Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial                       | https://chinicaltrials.gov/ct2/show/NC105988054 fterm=paragride&fank=1  |
| DAPA ACT HF          | 1.9  | https://clinicaltrials.gov/ct2/show/NCT04363697?term=DAPA+ACT+HF&draw=2&rank=1  |
|                      | Infarction 68  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating | https://clinicaltrials.gov/ctz/snow/NCTU4363697?term=DAPA+ACT+HF&draw=2&rank=1  |
|                      |  |   |
| FINE ARTS-HF         | Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection               |   |
|                      | Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%   | https://clinicaltrials.gov/ct2/show/NCT04435626?term=20103&draw=2&rank=1  |
| EMPACT MI            | A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a                    |   |
| 2.111 / 10.1 11.1    | Heart Attack (Myocardial Infarction)   | https://clinicaltrials.gov/ct2/show/NCT04509674?term=empact+mi&draw=2&rank=1  |
|                      |  |   |
| Device Trials        | Trial Title  | ClinicalTrials.gov Link   |
|                      |  | https://clinicaltrials.gov/ct2/show/NCT04201132?term=04201132&draw=2&rank=1   |
| PERFORMANCE II       | Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System                                   | receptify formed and sign for the first formed and |
| LUX Dx PERFORM       | LUX-Dx Insertable Cardiac Monitor Remote Programming and Performance Study   | https://clinicaltrials.gov/ct2/show/NCT04732728?term=lux+dx+perform&draw=2&rank=1   |
| EON BAT EM ONM       | Tear or marked earlies memory remote 110g/amming and 1 errormance aces;  |   |
| General Cardiology   | Trial Title  | ClinicalTrials.gov Link   |
| l l                  | Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the                | annount manager announced   |
| AEGIS-II             | Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome   | https://clinicaltrials.gov/ct2/show/NCTo3473223?cond=CSL112&rank=1  |
| RAPID (NODE-301)     | Efficacy and Safety of Estripamil for the Termination of Spontaneous PSVT  | https://clinicaltrials.gov/ct2/show/NCTo3464o19?term=NCTo3464o19&rank=1   |
|                      |  |   |
| NODE-303             | Safety Study of Etripamil Nasal Spray for Patients With Paroxysmal Supraventricular Tachycardia                            | https://clinicaltrials.gov/ct2/show/NCT04072835?term=NODE-303&draw=2&rank=1   |
| NODE-X               |  |   |
| HORIZON Outcomes     | Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients                    |   |
|                      | With CVD (Lp(a)HORIZON)  | https://clinicaltrials.gov/ct2/show/NCT04023552?term=CTQJ230A12301&draw=2&rank=1  |
| ORION-4              | A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With                              |   |
| 010014               | Cardiovascular Disease   | https://clinicaltrials.gov/ct2/show/NCT03705234?term=orion-4&rank=1   |
| SURPASS              | The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2                |   |
| 30117 A33            | Diabetes   |   |
| VESALIUS-CV          |  |   |
| VESALIUS-CV          | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke                 | https://clinicaltrials.gov/ct2/show/NCT03872401?term=03872401&rank=1  |
| DACIFIC AND          | Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in                   |   |
| PACIFIC AMI          | Patients Following an Acute Heart Attack   | https://clinicaltrials.gov/ct2/show/NCT04304534?term=pacific+ami&draw=2&rank=1  |

https://clinicaltrials.gov/ct2/show/NCT04610892?term=GOLDILOX&draw=2&rank=1

Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction